Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.

MLA

Aebersold, Helena, et al. “Patients on Vitamin K Treatment: Is Switching to Direct-Acting Oral Anticoagulation Cost-Effective? A Target Trial on a Prospective Cohort.” Open Heart (2053-3624), vol. 11, no. 1, June 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1136/openhrt-2023-002567.

APA

Aebersold, H., Foster-Witassek, F., Aeschbacher, S., Beer, J. H., Blozik, E., Blum, M., Bonati, L., Conte, G., Coslovsky, M., De Perna, M. L., Di Valentino, M., Felder, S., Huber, C. A., Moschovitis, G., Mueller, A., Paladini, R. E., Reichlin, T., Rodondi, N., Stauber, A., & Sticherling, C. (2024). Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort. Open Heart (2053-3624), 11(1), 1–11. https://doi.org/10.1136/openhrt-2023-002567

Chicago

Aebersold, Helena, Fabienne Foster-Witassek, Stefanie Aeschbacher, Juerg H. Beer, Eva Blozik, Manuel Blum, Leo Bonati, et al. 2024. “Patients on Vitamin K Treatment: Is Switching to Direct-Acting Oral Anticoagulation Cost-Effective? A Target Trial on a Prospective Cohort.” Open Heart (2053-3624) 11 (1): 1–11. doi:10.1136/openhrt-2023-002567.